Mirdametinib
( DrugBank: Mirdametinib / KEGG DRUG: Mirdametinib )
4 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
34 | Neurofibromatosis | 3 |
278 | Huge lymphatic malformation with cervicofacial lesion | 1 |
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
279 | Huge venous malformation with cervical, oral and pharyngeal diffuse lesion | 1 |
280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 1 |
34. Neurofibromatosis
Clinical trials : 165 / Drugs : 189 - (DrugBank : 83) / Drug target genes : 93 - Drug target pathways : 209
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
278. Huge lymphatic malformation with cervicofacial lesion
Clinical trials : 32 / Drugs : 32 - (DrugBank : 12) / Drug target genes : 8 - Drug target pathways : 136
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion
Clinical trials : 24 / Drugs : 24 - (DrugBank : 12) / Drug target genes : 6 - Drug target pathways : 132
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 29 / Drugs : 31 - (DrugBank : 15) / Drug target genes : 12 - Drug target pathways : 163
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|